NetworkNewsBreaks – ArQule, Inc. (NASDAQ: ARQL) Doses First Patient in Phase 1 Trial of ARQ 531 for B-cell Malignancies
ArQule (NASDAQ: ARQL) this morning said that the first patient has been dosed in its phase 1a/b trial with ARQ 531 in patients with B-cell malignancies that do not respond well to other approved therapies. ARQ 531 is an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). The phase 1a portion of the trial aims to establish a recommended dose through a dose escalation study open to all refractory patients. The company’s goal for the phase 1b portion will be to establish proof of concept and early signs of activity. “Our…







